DR. RICHARD ALLEYNE ARTIM, M.D.

FORT WORTH, TX

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 1 publication 1992 – 1992 NPI: 1205830619
Internal Medicine - Hematology & Oncology
Antineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyMultiple MyelomaRemission InductionSurvival AnalysisCyclophosphamideVincristinePrednisoneRadiotherapyMelphalan

Practice Location

710 W LEUDA ST
FORT WORTH, TX 76104-3114

Phone: (817) 921-9648

What does RICHARD ARTIM research?

Dr. Artim studies advanced multiple myeloma, which is a type of cancer affecting plasma cells in the bone marrow. He investigates how combining chemotherapy with hemibody radiotherapy, a targeted type of radiation therapy affecting large areas of the body, can help patients with high tumor burden. His work aims to provide doctors with new insights into managing this challenging condition and improving treatment protocols.

Key findings

  • Out of 72 patients, 22 achieved complete remission after initial chemotherapy, showing a positive response to treatment.
  • An additional 4 patients reached remission after receiving both radiation therapy and further chemotherapy.
  • Despite the safety of the treatment resulting in no major complications reported in community clinics, the overall survival rate was not significantly improved compared to other methods, with an average survival of 134 weeks.

Frequently asked questions

Does Dr. Artim study multiple myeloma?
Yes, Dr. Artim specifically studies advanced multiple myeloma and its treatment options.
What treatments has Dr. Artim researched?
He has researched the combination of chemotherapy and hemibody radiotherapy for patients with high-tumor-burden multiple myeloma.
Is Dr. Artim's work relevant to patients with high tumor burden?
Yes, his research directly addresses treatment strategies for patients with high tumor burden in multiple myeloma.

Publications in plain English

Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma.

1992

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

MacKenzie MR, Wold H, George C, Gandara D, Ray G +5 more

Plain English
This study looked at a treatment approach for patients with advanced multiple myeloma, a type of blood cancer. Researchers tested giving chemotherapy first for eight cycles, followed by hemibody radiation therapy and more chemotherapy. Out of 72 patients, 22 had a complete recovery after the initial treatment, and the overall survival time was about 134 weeks, which was similar to other treatments. This matters because it shows that while the treatment was safe and could be done in community healthcare settings, it didn't lead to longer survival compared to existing options. Who this helps: This helps patients with high-tumor-burden multiple myeloma and their doctors.

PubMed

Frequent Co-Authors

M R MacKenzie H Wold C George D Gandara G Ray S Schiff J Shields H Davidson F Meyers

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.